



(51) International Patent Classification:

A61K 9/127 (2006.01) A61K 47/42 (2017.01)
A61K 31/7088 (2006.01) A61K 48/00 (2006.01)
A61K 47/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/054769

(22) International Filing Date:

13 October 2021 (13.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/090,985 13 October 2020 (13.10.2020) US

(71) Applicant: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3600 Civic Center Boulevard, 9th Floor, Philadelphia, PA 19104 (US).

(72) Inventors: **PARHIZ, Hamideh**; 3131 Walnut St, Unit 645, Philadelphia, PA 19104 (US). **WEISSMAN, Drew**; 614 S. Hancock St., Philadelphia, PA 19147 (US). **TOMBACZ, Istvan**; 2101 Chesnut St, Unit 1106, Philadelphia, PA 19103 (US).

(74) Agent: **FONVILLE, Natalie, C.** et al.; Riverside Law, LLP, 175 Strafford Ave., Suite 100, Wayne, PA 19087 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS




Fig. 1

(57) Abstract: The present invention relates to compositions comprising a delivery vehicle conjugated to a T cell targeting domain, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to a T cell antigen. The invention also relates to methods of treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described compositions.

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))